The Smart 401(k) Rollover Option That Almost Everyone Forgets
When It Comes to Data Collection, Which Companies Can You Trust?
Careless Chinese Baggage Handler Really Throws Himself Into His Work
FedEx Earnings Plummet as Consumers Seek Cheaper Options
NASDAQ: ATHX
Athersys reports on progress in Phase 2 study of MultiStem for ischemic stroke
Athersys Reports on Progress in Phase 2 Study of MultiStem for Ischemic Stroke
Can Stem Cells Regenerate Your Portfolio? Stephen Dunn Says Yes
Athersys CEO to Present on September 24, 2012 at the Noble Financial Life Sciences Exposition
IBC Life Sciences to hsot a conference
The Next Big Growth Sector In Health Care: Stem Cell Therapy
Drug buoys Cleveland company's stem-cell aspiration
Osiris Stem Cell Drug Approval Bodes Well For Athersys
Athersys Management Discusses Q2 2012 Results - Earnings Call Transcript
Athersys reports Q2 EPS (13c), consensus (14c)
